Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 9 Farrerol alleviates high glucose and free fatty acid-induced endothelial cell dysfunction via inhibition of miR-29b-3p. A and B: Representative immunofluorescence images and quantitative analysis of the intensity endothelial anchoring junctions (VE-cadherin). Bar = 100 μm. n = 6; C and D: Representative images of immunofluorescence staining of intercellular adhesion molecule-1 (VCAM-1) and quantitative analysis of VCAM-1 intensity. Bar = 20 μm. n = 6; E-G: Western blots analysis and quantitative data of VCAM-1 and endothelial nitric oxide synthase expression in high glucose and free fatty acid treated endothelial cells (n = 3). ^aP < 0.05 vs NC; ^bP < 0.05 vs HG/FFA + mimic NC; ^cP < 0.05 vs HG/FFA + miR-29b-3p mimic; ^dP < 0.05 vs HG/FFA + FA + mimic NC. eNOS: Endothelial nitric oxide synthase; ICAM-1: Intercellular adhesion molecule-1; HG/FFA: High glucose and free fatty acid; FA: Farrerol.